Klogene is single-gene focused (Klotho), targeting multiple indications, using a variety of approaches to modulate gene expression. The company is headquartered in Boston and uses primarily a virtual company model. In addition to the strong research ties to Boston University School of Medicine and Universitat Autonoma de Barcelona, the company has signed formal collaboration agreements with leading academic and industry research teams in a number of disease areas, as well as general viral vector research and production required for gene therapy. The company has active programs in small molecules development and gene therapy. Its intellectual property includes direct use of the Klotho protein and CRISPR gene editing. Klogene’s active pre-clinical projects include cognition, Alzheimer’s, kidney disease and cancer.
We dare to be first in the pursuit of novel therapeutic strategies, striving to improve the lives of those afflicted by debilitating diseases.
We are excited about our research programs and are passionate about the efforts to take them to the clinic.
We make decisions based on facts, we do what we promise, we execute our plans while being financially conservative.
We show respect to all of our constituents by being ethical, open, honest and fair.